Fintel reports that on February 12, 2025, Morgan Stanley downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 433.54% Upside As of January 29,

As previously reported, Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed the firm’s prior $18

Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform. Published first on TheFly – the ultimate source for

James made a notable change in their assessment of Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), downgrading the biotechnology company's stock rating from Outperform to Market Perform. According to InvestingPro data,